NO20082145L - Prolinamidderivater som natriumkanalmodulatorer - Google Patents

Prolinamidderivater som natriumkanalmodulatorer

Info

Publication number
NO20082145L
NO20082145L NO20082145A NO20082145A NO20082145L NO 20082145 L NO20082145 L NO 20082145L NO 20082145 A NO20082145 A NO 20082145A NO 20082145 A NO20082145 A NO 20082145A NO 20082145 L NO20082145 L NO 20082145L
Authority
NO
Norway
Prior art keywords
sodium channel
channel modulators
prolinamide derivatives
prolinamide
derivatives
Prior art date
Application number
NO20082145A
Other languages
English (en)
Inventor
Giuseppe Alvaro
Markus Bergauer
Riccardo Giovannini
Roberto Profeta
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0520581A external-priority patent/GB0520581D0/en
Priority claimed from GB0523045A external-priority patent/GB0523045D0/en
Priority claimed from GB0603900A external-priority patent/GB0603900D0/en
Priority claimed from GB0618336A external-priority patent/GB0618336D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20082145L publication Critical patent/NO20082145L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Det er beskrevet en forbindelse av formel (I), et solvat, et salt eller promedikament derav, som er nyttig ved behandling av sykdommer og lidelser formidlet ved modulering av bruksavhengige spenndingsstyrte natriumkanaler.
NO20082145A 2005-10-10 2008-05-07 Prolinamidderivater som natriumkanalmodulatorer NO20082145L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0520581A GB0520581D0 (en) 2005-10-10 2005-10-10 Novel compounds
GB0523045A GB0523045D0 (en) 2005-11-11 2005-11-11 Novel compounds
GB0603900A GB0603900D0 (en) 2006-02-27 2006-02-27 Novel compounds
GB0618336A GB0618336D0 (en) 2006-09-18 2006-09-18 Novel compounds
PCT/EP2006/009731 WO2007042239A1 (en) 2005-10-10 2006-10-06 Prolinamide derivatives as sodium channel modulators

Publications (1)

Publication Number Publication Date
NO20082145L true NO20082145L (no) 2008-05-07

Family

ID=37546777

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082145A NO20082145L (no) 2005-10-10 2008-05-07 Prolinamidderivater som natriumkanalmodulatorer

Country Status (20)

Country Link
US (2) US7655693B2 (no)
EP (1) EP1934177B8 (no)
JP (1) JP5139305B2 (no)
KR (1) KR101282464B1 (no)
AR (1) AR056575A1 (no)
AT (1) ATE556049T1 (no)
AU (1) AU2006301470B2 (no)
BR (1) BRPI0616944B8 (no)
CA (1) CA2625642C (no)
CR (1) CR9898A (no)
EA (1) EA015736B1 (no)
ES (1) ES2387405T3 (no)
IL (1) IL192627A0 (no)
MA (1) MA29817B1 (no)
NO (1) NO20082145L (no)
NZ (1) NZ567051A (no)
PE (1) PE20070592A1 (no)
PL (1) PL1934177T3 (no)
TW (1) TW200730494A (no)
WO (1) WO2007042239A1 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8143306B2 (en) * 2005-10-10 2012-03-27 Convergence Pharmaceuticals Limited Methods of treating bipolar disorders
ATE472529T1 (de) * 2005-10-10 2010-07-15 Glaxo Group Ltd Prolinamidderivate als natriumkanalmodulatoren
GB0701365D0 (en) * 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0706630D0 (en) * 2007-04-04 2007-05-16 Glaxo Group Ltd Novel compounds
WO2011015537A1 (en) * 2009-08-05 2011-02-10 Glaxo Group Limited Co-therapy for the treatment of epilepsy and related disorders
WO2011029762A1 (en) * 2009-09-14 2011-03-17 Convergence Pharmaceuticals Limited Process for preparing alpha-carboxamide derivatives
EP2681200A4 (en) 2011-03-03 2015-05-27 Zalicus Pharmaceuticals Ltd INHIBITORS OF BENZIMIDAZOLE TYPE OF SODIUM CHANNEL
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
GB201209015D0 (en) 2012-05-22 2012-07-04 Convergence Pharmaceuticals Novel compounds
WO2015130905A1 (en) 2014-02-27 2015-09-03 Merck Patent Gmbh Heterocyclic compounds as nav channel inhibitors and uses thereof
GB201417499D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417500D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417497D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
ES2912881T3 (es) * 2014-12-23 2022-05-30 Convergence Pharmaceuticals Procedimiento para preparar derivados de alfa-carboxamida pirrolidina
WO2018085521A2 (en) * 2016-11-02 2018-05-11 Biogen Inc. Novel dosage regimen
US20200062705A1 (en) * 2017-05-19 2020-02-27 Biogen Ma Inc. Novel crystalline forms
EP3691634A4 (en) * 2017-10-05 2021-03-31 Biogen Inc. PROCESS FOR THE PREPARATION OF PYRROLIDINE ALPHA-CARBOXAMIDE DERIVATIVES
JP2020536898A (ja) 2017-10-10 2020-12-17 バイオジェン インコーポレイテッド スピロ誘導体を調製するためのプロセス
CA3093401A1 (en) * 2018-04-16 2019-10-24 Biogen Ma Inc. Methods of treating neuropathic pain
EP3953328A4 (en) * 2019-04-10 2023-03-08 Biogen Inc. PROCESS FOR THE PREPARATION OF ALPHA CARBOXAMIDE PYROLIDINE DERIVATIVES
AU2020271856A1 (en) * 2019-04-10 2021-12-02 Biogen Ma Inc. Process for preparing alpha-carboxamide pyrrolidine derivatives
WO2021154631A1 (en) 2020-01-30 2021-08-05 Javed Mohammad Combination drug therapies for cns disorders

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94466A (en) 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US6201016B1 (en) 1994-06-27 2001-03-13 Cytomed Incorporated Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
US6136131A (en) * 1998-06-02 2000-10-24 Instrument Specialties Company, Inc. Method of shielding and obtaining access to a component on a printed circuit board
TR200102790T2 (tr) 1999-03-26 2002-06-21 Euro-Celtique S.A. Aril İkameli Pirazoller, İmidazoller, Oksazoller, Tiazoller ve Piroller Ve Bunların Kullanımı.
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
GB0115517D0 (en) * 2001-06-25 2001-08-15 Ferring Bv Novel antidiabetic agents
TW200404796A (en) * 2002-08-19 2004-04-01 Ono Pharmaceutical Co Nitrogen-containing compound
MY134480A (en) 2002-09-20 2007-12-31 Hoffmann La Roche 4-pyrrolidino-phenyl-benzyl ether derivatives
MY142651A (en) 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
CN1798738A (zh) 2003-04-03 2006-07-05 麦克公司 作为钠通道阻滞剂的联芳基取代吡唑
CA2522476A1 (en) 2003-04-18 2004-11-04 Merck & Co., Inc. Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers
WO2005000309A2 (en) * 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
EP1524265A1 (en) 2003-10-15 2005-04-20 Newron Pharmaceuticals S.p.A. Prolinamide derivatives as sodium and/or calcium channel blockers or selective MAO-B inhibitors
WO2005100334A1 (en) * 2004-04-14 2005-10-27 Pfizer Products Inc. Dipeptidyl peptidase-iv inhibitors
US7858786B2 (en) 2005-05-04 2010-12-28 Vertex Pharmaceuticals Incoropated Pyrimidines and pyrazines useful as modulators of ion channels
WO2006119390A1 (en) 2005-05-04 2006-11-09 Vertex Pharmaceuticals Incorporated Pyridines useful as modulators of ion channels
EP1888549A2 (en) 2005-05-19 2008-02-20 Vertex Pharmaceuticals, Inc. Biaryls useful as modulators of ion channels
WO2007028654A1 (en) * 2005-09-09 2007-03-15 Smithkline Beecham Corporation Pyridine derivatives and their use in the treatment of psychotic disorders
ATE472529T1 (de) 2005-10-10 2010-07-15 Glaxo Group Ltd Prolinamidderivate als natriumkanalmodulatoren
TW200728258A (en) * 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
GB0701366D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
WO2008090114A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
GB0701365D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0706630D0 (en) 2007-04-04 2007-05-16 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
US20080280969A1 (en) 2008-11-13
EP1934177B8 (en) 2012-09-05
PL1934177T3 (pl) 2013-03-29
MA29817B1 (fr) 2008-09-01
US7655693B2 (en) 2010-02-02
US20100105754A1 (en) 2010-04-29
AR056575A1 (es) 2007-10-10
CA2625642C (en) 2013-12-24
ATE556049T1 (de) 2012-05-15
CA2625642A1 (en) 2007-04-19
JP2009511519A (ja) 2009-03-19
AU2006301470A1 (en) 2007-04-19
EP1934177B1 (en) 2012-05-02
US8153681B2 (en) 2012-04-10
TW200730494A (en) 2007-08-16
AU2006301470B2 (en) 2012-06-14
PE20070592A1 (es) 2007-06-23
CR9898A (es) 2008-07-29
KR20080059296A (ko) 2008-06-26
IL192627A0 (en) 2011-08-01
BRPI0616944B1 (pt) 2020-04-14
EP1934177A1 (en) 2008-06-25
WO2007042239A1 (en) 2007-04-19
BRPI0616944B8 (pt) 2021-05-25
NZ567051A (en) 2011-03-31
JP5139305B2 (ja) 2013-02-06
ES2387405T3 (es) 2012-09-21
BRPI0616944A2 (pt) 2011-07-05
KR101282464B1 (ko) 2013-07-04
EA015736B1 (ru) 2011-10-31
EA200801054A1 (ru) 2008-08-29

Similar Documents

Publication Publication Date Title
NO20082145L (no) Prolinamidderivater som natriumkanalmodulatorer
ATE472529T1 (de) Prolinamidderivate als natriumkanalmodulatoren
MX2007007845A (es) Sulfonilpirrolidinas, metodo para producir las mismas y su uso como medicamento.
TW200728258A (en) Novel compounds
NO20081788L (no) Cyklopropylaminer som modulatorer av histamin-H3-reseptoren
MX2009002002A (es) Derivados de 4-(n-azacicloalquil) anilidas como moduladores de canal de potasio.
EA201001848A1 (ru) Производные пиразина в качестве блокаторов эпителиальных натриевых каналов
NO20056130L (no) Nye substituerte 3-svovelindoler
NO20063576L (no) 1,3-dioksanederivativer og analoge forbindelser for behandling av fedme og diabetes
NO20083220L (no) Heterocykliske derivater som modulatorer for ionekanaler
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
NO20061092L (no) Heteroarvlaminosulfonvlfenvl-derivater for anvendelse som natrium- eller kalslumkanalblokkere i behandlingen av smerte
EA201000886A1 (ru) Органические соединения
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
NO20076306L (no) Bicykliske derivater som modulatorer av ionekanaler
WO2007067711A3 (en) Certain chemical entities, compositions, and methods for modulating trpv1
NO20081846L (no) Bifenylderivater og deres anvendelse ved behandling av hepatitt C
NO20055894L (no) Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer
NO20060688L (no) Fusjonerte aryl- og heteroarylderivater som modulatorer av metabolisme og profylakse og behandling av lidelser relatert til dette
NO20073926L (no) Pyrazolforbindelser som modulerer aktivitet av CDK-, GSK- og aurorakinaser
MY148538A (en) Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
NO20085029L (no) Substituerte pyridylamidforbindelser som modulatorer av histamin H3 reseptoren
EA200600203A1 (ru) Производные 2-(хиноксалин-5-илсульфониламино)бензамида в качестве модуляторов сск2
CY1112921T1 (el) Ενεργοποιητες γλυκοκινασης πυρρολιδινονης

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application